X0306 4 2021-01-22 1 0001714798 Prevail Therapeutics Inc. PRVL 0001298669 Adams Timothy M C/O PREVAIL THERAPEUTICS INC. 430 EAST 29TH STREET, SUITE 1520 NEW YORK NY 10016 1 0 0 0 Stock Option (Right to Buy) 10.26 2021-01-22 4 D 0 32400 0.00 D Common Stock 32400 0 D Stock Option (Right to Buy) 16.98 2021-01-22 4 D 0 17000 0.00 D Common Stock 17000 0 D Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Capitalized terms used herein without definition have the meanings ascribed to them in the Agreement and Plan of Merger, dated as of December 24, 2020, by and among the Issuer, Eli Lilly and Company and Tyto Acquisition Corporation (the "Merger Agreement"). /s/ Brett Kaplan, Attorney-in-Fact 2021-01-26